-
公开(公告)号：US20170246167A1
公开(公告)日：2017-08-31
申请号：US15443145
申请日：2017-02-27
Applicant: Rigel Pharmaceuticals, Inc
Inventor： Rajinder Singh , Ankush Argade , Donald G. Payan , Susan Molineaux , Sacha J. Holland , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Catherine Sylvain , Hui Li , Alexander B. Rossii
IPC: A61K31/505 , A61K31/5377 , A61K31/506
CPC classification number: A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/5395 , A61K31/551 , A61K45/06 , C07D239/48 , C07D265/36 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D407/14 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D495/04 , C07D498/04 , C07D498/14 , C07F5/027
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
-
公开(公告)号：US09540334B2
公开(公告)日：2017-01-10
申请号：US14812829
申请日：2015-07-29
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Rajinder Singh , Ankush Argade , Donald G. Payan , Susan Molineaux , Sacha J. Holland , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Catherine Sylvain , Hui Li , Alexander B. Rossi
IPC: C07D239/48 , A61K31/505 , A61K31/519 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/551 , A61K45/06 , C07D498/04 , C07D265/36 , A61K31/5395 , C07D495/04 , C07F5/02 , C07D498/14 , C07D407/14
CPC classification number: A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/5395 , A61K31/551 , A61K45/06 , C07D239/48 , C07D265/36 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D407/14 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D495/04 , C07D498/04 , C07D498/14 , C07F5/027
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
-
公开(公告)号：US20160009660A1
公开(公告)日：2016-01-14
申请号：US14858661
申请日：2015-09-18
Applicant: Rigel Pharmaceuticals, Inc
Inventor： Rajinder Singh , Ankush Argade , Donald G. Payan , Susan Molineaux , Sacha J. Holland , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Catherine Sylvain , Hui Li , Alexander B. Rossi
IPC: C07D239/48
CPC classification number: A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/5395 , A61K31/551 , A61K45/06 , C07D239/48 , C07D265/36 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D407/14 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D495/04 , C07D498/04 , C07D498/14 , C07F5/027
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
-
公开(公告)号：US08853397B2
公开(公告)日：2014-10-07
申请号：US13759835
申请日：2013-02-05
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Rajinder Singh , Ankush Argade , Donald G. Payan , Susan Molineaux , Sacha J. Holland , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Catherine Sylvain , Hui Li , Alexander B. Rossi
IPC: C07D239/48 , A61K31/506 , C07D413/12 , C07D401/12 , A61K31/551 , C07D409/12 , C07D409/14 , A61K31/538 , C07D417/12 , A61K31/519 , C07D405/14 , C07D401/14 , C07D403/14 , C07D265/36 , A61K31/5383 , A61K31/505 , A61K45/06 , C07D413/10 , C07D413/14 , A61K31/5377 , C07D498/04 , C07D405/12 , C07D417/14 , C07D403/12
CPC classification number: A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/5395 , A61K31/551 , A61K45/06 , C07D239/48 , C07D265/36 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D407/14 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D495/04 , C07D498/04 , C07D498/14 , C07F5/027
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
-
公开(公告)号：US08822685B2
公开(公告)日：2014-09-02
申请号：US13961780
申请日：2013-08-07
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Rajinder Singh , Ankush Argade , Donald G. Payan , Susan Molineaux , Sacha J. Holland , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Catherine Sylvain , Hui Li , Alexander B. Rossi
IPC: C07D239/48 , A61K31/505 , C07D405/14 , A61K31/551 , C07D403/12 , C07D409/14 , A61K31/5383 , C07D413/14 , C07D413/10 , A61K31/5377 , C07D405/12 , C07D265/36 , C07D401/14 , C07D498/04 , C07D409/12 , A61K31/519 , C07D401/12 , C07D417/14 , C07D403/14 , C07D413/12 , A61K31/506 , A61K31/538 , C07D417/12 , A61K45/06
CPC classification number: A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/5395 , A61K31/551 , A61K45/06 , C07D239/48 , C07D265/36 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D407/14 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D495/04 , C07D498/04 , C07D498/14 , C07F5/027
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
-
Patent Agency Ranking
公开(公告)号：US08748597B2
公开(公告)日：2014-06-10
申请号：US13909830
申请日：2013-06-04
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Rajinder Singh , Ankush Argade , Catherine Sylvain
IPC: C07D265/36
CPC classification number: A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/5395 , A61K31/551 , A61K45/06 , C07D239/48 , C07D265/36 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D407/14 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D495/04 , C07D498/04 , C07D498/14 , C07F5/027
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
-
公开(公告)号：US20200085820A1
公开(公告)日：2020-03-19
申请号：US16691352
申请日：2019-11-21
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Rajinder Singh , Ankush Argade , Donald Payan , Susan Molineaux , Sacha J. Holland , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Catherine Sylvain , Hui Li , Alexander B. Rossi
IPC: A61K31/505 , A61K31/519 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D239/48 , C07D417/14 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/551 , A61K45/06 , C07D498/04 , C07D265/36 , A61K31/5395 , C07D495/04 , C07F5/02 , C07D498/14 , C07D407/14
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
-
公开(公告)号：US20190255047A1
公开(公告)日：2019-08-22
申请号：US16402912
申请日：2019-05-03
Applicant: Rigel Pharmaceuticals, Inc
Inventor： Rajinder Singh , Ankush Argade , Donald G. Payan , Susan Molineaux , Sacha J. Holland , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Catherine Sylvain , Hui Li , Alexander B. Rossi
IPC: A61K31/505 , C07D498/04 , C07D495/04 , A61K31/551 , A61K31/5383 , A61K31/538 , A61K31/5377 , A61K31/506 , A61K31/5395 , C07D265/36 , C07D417/14 , C07D417/12 , C07D413/14 , C07D413/12 , C07D413/10 , C07D409/14 , C07D409/12 , C07D405/14 , C07D405/12 , C07D403/14 , C07D403/12 , C07D401/14 , C07D401/12 , C07D239/48 , A61K31/519 , C07D407/14 , C07D498/14 , C07F5/02 , A61K45/06
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
-
公开(公告)号：US20170081290A1
公开(公告)日：2017-03-23
申请号：US15366931
申请日：2016-12-01
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Rajinder Singh , Ankush Argade , Donald G. Payan , Susan Molineaux , Sacha J. Holland , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Catherine Sylvain , Hui Li , Alexander B. Rossi
IPC: C07D239/48 , C07D409/12 , C07D403/12 , C07D409/14 , C07D413/12 , C07D403/14 , C07D405/14 , C07D405/12 , C07D417/12
CPC classification number: A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/5395 , A61K31/551 , A61K45/06 , C07D239/48 , C07D265/36 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D407/14 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D495/04 , C07D498/04 , C07D498/14 , C07F5/027
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
-
公开(公告)号：US09353126B2
公开(公告)日：2016-05-31
申请号：US14540323
申请日：2014-11-13
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Dane Goff , Jing Zhang , Catherine Sylvain , Rajinder Singh , Sacha Holland , Jiaxin Yu , Thilo J. Heckrodt , Pingyu Ding
IPC: C07D249/14 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D495/04 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/04 , C07D417/04 , C07D491/048
CPC classification number: A61K31/4196 , A61K31/428 , A61K31/4355 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/497 , A61K31/498 , A61K31/501 , A61K31/502 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/635 , C07D249/14 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/04 , C07D491/048 , C07D495/04
Abstract: Substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.
Abstract translation: 公开了含有这些化合物的取代的三唑和药物组合物可用于抑制受体蛋白酪氨酸激酶Ax1的活性。 还公开了使用该化合物治疗与Axl活性相关的疾病或病症的方法。
-
-
-
-
-
-
-
-
-
Search Results
38
records
(took 0.076 seconds)
